Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10585856 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TP53ERCC5FEN1HPGD | |
| SCHEMBL121698 | 0.84 | TMPRSS4 (0.44) | ALDH1A1TP53PDK2TSHRCASP1 | |
| SCHEMBL10580560 | 0.84 | TSHR (0.59) | ALDH1A1TP53ERCC5FEN1HPGD | |
| SCHEMBL145710 | 0.82 | CES1 (0.44) | ALDH1A1TP53HPGDLMNAALOX15 | |
| SCHEMBL3789805 | 0.82 | CES1 (0.45) | ALDH1A1TP53HPGDLMNATSHR | |
| SCHEMBL17149270 | 0.81 | PDK1 (0.45) | ALDH1A1TP53HPGDLMNAPDK2 | |
| SCHEMBL523743 | 0.81 | RECQL (0.53) | ALDH1A1TP53HPGDTSHRSMN1; SMN2 | |
| SCHEMBL20308952 | 0.81 | TRPV1 (0.39) | ALDH1A1TP53HPGDLMNAKDM4E | |
| SCHEMBL30094862 | 0.81 | JAK2 (0.54) | ALDH1A1HPGDLMNATSHRSMN1; SMN2 | |
| SCHEMBL29911166 | 0.81 | RECQL (0.53) | ALDH1A1TP53HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | claimed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| WO-2012097510-A1 | PROCESS FOR PREPARATION OF EFAVIRENZ BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097510-A1 | PROCESS FOR PREPARATION OF EFAVIRENZ BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097511-A1 | DMP-266 BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097511-A1 | DMP-266 BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012079235-A1 | PROCESS FOR PREPARING EFAVIRENZ | LONZA LTD (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012079235-A1 | PROCESS FOR PREPARING EFAVIRENZ | LONZA LTD (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | CYP3A4, CYP2C19, CYP3A43 | ALDH1A1 1319/4885TP53 4640/4885ERCC5 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.